Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
, /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, will release financial results for the third quarter (Q3) fiscal year 2026 after the close of regular trading on Thursday, July 30, 2026.
Members of Dolby management will lead a conference call open to all interested parties to discuss Q3 fiscal year 2026 financial results for Dolby Laboratories at 2:00 p.m. PT (5:00 p.m. ET) on Thursday, July 30, 2026.
The conference call can be accessed by registering online at Dolby Laboratories Q3 Fiscal Year 2026 Financial Results, at which time registrants will receive dial-in information as well as a conference ID.
A live audio webcast of the conference call will be available at http://investor.dolby.com where it will be archived for one year.
About Dolby Laboratories
Dolby Laboratories (NYSE: DLB) is a world leader in immersive entertainment. From movies and TV, to music, sports, gaming, and beyond, Dolby transforms the science of sight and sound into spectacular experiences for billions of people worldwide across all their favorite devices. We partner with artists, storytellers, and the brands you love to transform entertainment and digital experiences through groundbreaking innovations like Dolby Atmos, Dolby Vision, Dolby Cinema, and Dolby OptiView.
Dolby, Dolby Vision, Dolby Atmos, Dolby Cinema, Dolby OptiView and the double-D symbol are among the registered and unregistered trademarks of Dolby Laboratories in the United States and/or other countries.
Investor Contact:
Peter Goldmacher
Dolby Laboratories
[email protected]
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative to placebo in “pure” DLB and support selection of 50 mg TID for planned Phase 3 study in DLB
Neflamapimod produced durable slowing of basal forebrain atrophy and increased basal forebrain connectivity relative to placebo in trial, reinforcing the basal forebrain as a key therapeutic target in DLB
New Phase 2 study showed an 80 mg twice-daily dose of neflamapimod met its primary safety, tolerability, and pharmacokinetic objectives, with encouraging secondary findings on clinical activity
BOSTON, July 14, 2026 — CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company) presented new analyses this week highlighting insights into neflamapimod's treatment effects in DLB at the Alzheimer's Association International Conference (AAIC) 2026 in London. The analyses included treatment effects during the placebo-controlled portion of CervoMed’s Phase 2b clinical trial, as well as the impact of achieving higher plasma drug concentrations relative to placebo during the trial's extension phase. They also included pharmacokinetic-pharmacodynamic (PK-PD) relationships for neflamapimod and its effects on MRI measures of the underlying disease process in DLB.
“The analyses presented at AAIC provide consistent evidence across clinical, plasma biomarker, and imaging studies that neflamapimod has the potential to address the underlying cause of DLB and sharpen our understanding of the optimal dosing strategies to help achieve this outcome,” said Dr. John Alam, Chief Executive Officer of CervoMed. “These studies provide important insights for the implementation of neflamapimod’s planned Phase 3 trial, and we’re thrilled to be able to share them with the DLB community.”
Data presented at the conference included new analyses from the 159-patient Phase 2b RewinD-LB trial of neflamapimod, a 16-week randomized, double-blind, placebo-controlled study followed by a 32-week neflamapimod-only extension, as well as additional preclinical and clinical studies. Collectively, these analyses span neflamapimod's effects on disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy in DLB, along with the first data on the safety, tolerability, pharmacokinetics, and clinical activity of an 80 mg twice-daily (BID) dose.
Analyses Reinforce Observed Treatment Effect of Neflamapimod in “Pure” DLB and Support Planned Phase 3 Dose
In the placebo-controlled phase of the RewinD-LB trial, neflamapimod did not replicate the positive results seen in its earlier Phase 2a study, in which it improved outcomes on the Clinical Dementia Rating – Sum of Boxes (CDR-SB) scale versus placebo. CDR-SB is a scoring scale used to stage the severity of Alzheimer's disease and other dementias. The analyses presented at AAIC indicate that the failure of the study to replicate the Phase 2a results can be attributed to a combination of a higher-than-targeted proportion of patients with Alzheimer’s disease (AD) co-pathology (as determined by elevated plasma pTau181 levels at screening), and use of a neflamapimod drug product batch that did not achieve expected plasma drug concentrations. Specifically, exploratory analyses from RewinD-LB provide evidence that neflamapimod slowed worsening of DLB in patients with low plasma pTau181 and in those who achieved expected plasma drug concentrations.
Exploratory analyses of the placebo-controlled phase of RewinD-LB identified treatment effects favoring neflamapimod on CDR-SB, with a consistently improving treatment effect at progressively lower plasma pTau181 levels. The plasma pTau181 cut-off of <21 pg/mL has recently been identified in scientific literature as the optimal cut-off to exclude AD pathology. Further, the improvement relative to placebo observed in the subset of participants with pTau181 <21 pg/mL was limited to those patients who were above the median trough plasma drug concentration for the study as a whole.
These effects were also demonstrated by the extension-phase results, where a batch of capsules (DP Batch B) achieved higher plasma drug concentrations than the batch used during the placebo-controlled phase (DP Batch A). A within-participant comparison of DP Batch B demonstrated a significant improvement in change in CDR-SB compared to placebo (0.17 increase with DP Batch B during the extension vs. 0.95 with placebo in the same patients, p=0.005; NOTE: an increase in CDR-SB score indicates worsening of disease), while a within-subject improvement was not seen with DP Batch A.
Together, these analyses corroborate that the study's primary result was affected by the inclusion of patients with AD co-pathology and by lower-than-expected neflamapimod exposure in some patients. These findings support the patient population and dose selected for the Company’s planned Phase 3 trial in patients with DLB, for which the Company has gained alignment with US Food and Drug Administration (FDA), European Medicines Agency, Medicines and Healthcare products Regulatory Agency, and Pharmaceuticals and Medicines Devices Agency.
Neflamapimod Demonstrated Durable Slowing of Basal Forebrain Atrophy
Over the 16 weeks of the placebo-controlled period of the RewinD-LB trial, neflamapimod-treated participants demonstrated increased right basal forebrain (BF) volume relative to placebo, as measured by structural and functional MRI. BF atrophy is the primary pathogenic driver of disease expression and progression in DLB. Right basal forebrain volume remained stable over 48 weeks (placebo-controlled phase + extension) in participants receiving neflamapimod in both phases and stabilized after treatment initiation in the extension in prior placebo recipients.
Increases in functional connectivity between the right BF and the right default mode network (DMN) were also observed during the neflamapimod-only extension. Disruption in BF-DMN connectivity, marked by abnormal activity in these regions, has been linked to neurodegenerative disorders such as DLB.
The laterality of the treatment effect is consistent with published data showing that, in DLB, the neurodegeneration is more advanced in the left basal forebrain, potentially allowing for positive treatment effects to be more achievable on the right side.
New PK-PD Analysis and Phase 2 Study Results for Neflamapimod 80 mg BID in DLB Strengthen Understanding of Dosing
PK-PD Analysis
A new analysis showed that a consistent pharmacokinetic-pharmacodynamic relationship has been observed across nonclinical and clinical studies of neflamapimod, with a plasma trough drug concentration (Ctrough) threshold (~4 ng/mL) associated with biomarker and clinical improvements. The 4 ng/mL plasma threshold exceeds the in vitro concentration necessary to produce neflamapimod's primary pharmacologic effect, inhibition of interleukin-1β neurotoxic signaling.
Across the Company’s trials in DLB, observed clinical outcomes with neflamapimod have tracked with the proportion of patients who achieved the plasma Ctrough threshold of ~4 ng/mL:
% of Patients Achieving Ctrough
≥ 4 ng/mLObserved Clinical Outcomes40 mg BID
(Phase 2a only)25%No discernible activity40 mg TID Batch A
(Phase 2b)50%Marginal clinical activity, except potentially in those who achieve
Ctrough target40 mg TID Batch B
(Phase 2b)75%Demonstrated improvement on CDR-SB, CGIC and plasma GFAP
BID: twice daily; CDR-SB: Clinical Dementia Rating scale – Sum of Boxes; CGIC: clinical global impression of change; GFAP: glial fibrillary acidic protein; TID: three times daily
Based on the above findings, the dose for the Company's planned future trials has been selected to be 50 mg TID, which is expected to achieve at or above the plasma Ctrough threshold of ~4 ng/mL in approximately 90% of patients.
Phase 2 Study of Neflamapimod 80 mg BID in Patients with DLB
A separate study evaluated an alternative dose of neflamapimod, 80 mg BID, which met its primary objectives for safety, tolerability, and pharmacokinetics. The regimen was well tolerated, with no new safety signals identified over 24 weeks in 26 participants with DLB and achieved target trough plasma concentrations predicted to optimize p38α inhibition, though the increase in Ctrough observed relative to the 40 mg TID dose utilized in the Company’s prior clinical trials was not dose proportional.
"Our clinical study of neflamapimod 80 mg twice daily met its primary objectives for safety, tolerability and pharmacokinetics. Although the clinical findings should be interpreted cautiously because this was an open-label study, the findings on the secondary objective of clinical activity are also very encouraging and consistent with the findings in prior studies of neflamapimod in patients with DLB, showing stabilization of executive function and of global cognition and function, along with evidence of reduced neuropsychiatric symptoms," said Professor Frederic Blanc, the 80 mg BID study's principal investigator, professor of geriatrics, and neurologist at Strasbourg University Hospitals.
Evaluation of other exploratory clinical, plasma biomarker, and MRI endpoints is ongoing.
CervoMed’s poster presentations of the results described above will be accessible in the Events and Presentations section of CervoMed’s website, https://www.cervomed.com/, following the presentation.
About Dementia with Lewy Bodies
DLB is the second most common progressive dementia after AD, affecting millions worldwide. Patients may experience a combination of decline in cognitive function, cognitive fluctuations, visual hallucinations, and sleep disorders, as well as motor symptoms similar to Parkinson’s disease. There are no approved treatments for DLB in the United States or European Union, and the current standard-of-care therapies only temporarily relieve symptoms.
About Neflamapimod
Neflamapimod is an investigational, orally administered small-molecule drug that readily crosses the blood-brain barrier and selectively inhibits the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, recovery after ischemic stroke, and primary progressive aphasia.
In nonclinical studies, neflamapimod restored synaptic function within the basal forebrain cholinergic system, the brain region most affected in DLB. Across Phase 1 and 2 clinical trials involving more than 800 participants, the drug has been generally well tolerated and demonstrated consistent signals of efficacy. In the 91-patient Phase 2a AscenD-LB trial, neflamapimod significantly improved dementia severity and functional mobility in patients with DLB. Results from the 159-patient Phase 2b RewinD-LB trial, a 16-week randomized, double-blind, placebo-controlled trial followed by a 32-week neflamapimod-only extension, further supported neflamapimod’s potential to deliver meaningful clinical benefit, improving both cognitive and functional outcomes and showing a positive effect on a key blood biomarker of neurodegeneration during the extension phase. Across both studies, the greatest benefits were observed in patients without AD co-pathology. Collectively, these findings underscore the therapeutic promise and scientific validity of neflamapimod as a potential treatment for DLB and other degenerative brain disorders.
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology. In November 2025, CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB, and the Company is currently focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.
Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the Company’s need to acquire sufficient funding, including funding (through a strategic partnership or otherwise) for any Phase 3 trial in patients with DLB; the Company’s plan to focus on strategic partnering to advance neflamapimod into Phase 3 for DLB and the timing of entering into any such partnership, if at all; the therapeutic potential of neflamapimod in DLB, nfvPPA, amyotrophic lateral sclerosis, or any other indication, including the degree of sustainability of any therapeutic effects, its potential impact on the rate of disease progression and/or clinical worsening, the optimal dosing regimen to achieve therapeutic effects, or any other treatment effects observed in any clinical trial on any clinical, biomarker, or other outcome measure; the anticipated timing and achievement of clinical and development milestones, including the Company’s initiation of any Phase 3 trial in patients with DLB; the anticipated data readouts from the Company’s Phase 2a trial in nfvPPA and the anticipated dosing of the first patient with neflamapimod in the EXPERTS-ALS trial; any other expected or implied benefits or results, including the extent (if any) to which neflamapimod may demonstrate efficacy or other clinical or biomarker improvements in patients; and expectations with respect to neflamapimod, including the timing of any regulatory submissions and potential approvals thereof, if any, in DLB or any other indication. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms or at all, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials; the Company’s ability to successfully enter into a partnership to advance neflamapimod into Phase 3 for DLB in a timely manner, on acceptable terms, or at all; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA or other regulators; the Company’s ability to maintain the intellectual property protection afforded by the Company’s patent portfolio; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the US Securities and Exchange Commission (SEC) on March 13, 2026, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.
SummaryCognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA’s feedback gave their planned pivotal program a clearer path.Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data.CGTX’s SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and delusion benefits.I do believe their narrowed focus helps to some extent. Still, CGTX’s runway only lasts into Q2 2027, while the pivotal start is expected around mid-2027.So, despite its potential dilution risks, I feel CGTX’s zervimesine potential for DLB warrants a speculative “Buy” at an EV of just $71.9 million. Richard Drury/DigitalVision via Getty Images
Cognition Therapeutics, Inc. (CGTX) is a biopharmaceutical company developing a small-molecule drug called zervimesine. This asset is targeted for age-related neurodegenerative disorders, principally dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD). Based on the results of the Phase
3.48K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
June 24, 2026 07:30 ET | Source: Cognition Therapeutics, Inc.
- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease -
- Company Developing NPI as a Measure of DLB Psychosis -
PURCHASE, N.Y., June 24, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, today announced that it received written feedback from the U.S. Food and Drug Administration (FDA) following its recent meeting. The FDA agreed that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome and reached alignment with the Company on key aspects of a pivotal trial to support a New Drug Application (NDA). The registrational program is expected to begin in mid-2027.
As discussed with the FDA, Cognition expects the Phase 3 study will enroll people with DLB who experience psychosis symptoms of hallucinations and delusions. Patients receiving stable background treatment with off-label antipsychotic medications will be eligible. Following screening, participants will be randomized to receive either 100 mg of once-daily oral zervimesine or placebo for nine months. The company will work with the FDA on the analytical and statistical details for the use of the neuropsychiatric inventory (NPI) as a novel primary endpoint for a pivotal trial in DLB psychosis.
“We reached an important agreement with the FDA that DLB psychosis could be an approvable outcome and that key aspects of our registrational trial design are appropriate and supportive of a NDA,” explained Anthony O. Caggiano, MD, PhD, chief medical officer of Cognition. “To date, few drugs have been researched for DLB and none have been approved. The only recourse for DLB patients experiencing psychosis is the off-label use of potentially dangerous antipsychotics.”
The proposed Phase 3 study builds on findings from Cognition's Phase 2 COG1201 ‘SHIMMER’ trial in mild-to-moderate DLB, which demonstrated improvements in psychosis symptoms with zervimesine versus placebo as measured by the NPI. In a recent analysis of results from the Phase 2 study, zervimesine slowed progression of hallucinations and delusions by 89%. In July, the Company will present additional analyses from the Phase 2 study showing zervimesine’s impact on the hallucination and delusion components of the NPI at the Alzheimer’s Association’s International Conference (AAIC).
“Working with the FDA, we intend to find a path forward for a patient population that has waited too long,” said Lisa Ricciardi, president and CEO. “Our ultimate goal is to provide patients and their families with a durable treatment option for DLB psychosis that actually slows the progression of hallucinations and delusions.”
About Cognition Therapeutics
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy, Parkinson’s, among others. The company’s lead candidate, zervimesine (CT1812), is an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer’s disease. Backed by nearly $200 million in National Institutes of Health and related foundation grants, Cognition Therapeutics continues to advance clinical research in its efforts to bring forth solutions that meet patients where they are and reduce caregiver burden. Learn more at cogrx.com.
About DLB Psychosis
Dementia with Lewy bodies (DLB) is a progressive, fatal neurodegenerative disease characterized by neuropsychiatric, cognitive and motor deficits. Up to 80% of people living with DLB experience psychosis, which manifests primarily as debilitating hallucinations and delusions. These symptoms are frequently cited as the most challenging for patients and their care partners to manage. There are no FDA-approved drugs for DLB, and the off-label use of traditional antipsychotics is often avoided due to the risk of severe and potentially life-threatening adverse reactions, underscoring a critical unmet need.
About Zervimesine (CT1812)
Zervimesine (CT1812) is currently being studied in the Phase 2 START Study (NCT05531656) in patients with MCI and early Alzheimer’s disease. Phase 2 clinical studies have concluded in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease, and geographic atrophy secondary to dry AMD. Based in part on the strong efficacy signals observed in the Phase 2 SHIMMER study in DLB (NCT05225415), the company plans to advance zervimesine into a late-stage clinical trial for people with DLB psychosis. Zervimesine has been generally well tolerated in clinical studies to date.
The USAN Council has adopted zervimesine as the United States Adopted Name (USAN) for CT1812.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine, any analyses of the results therefrom, as well as statements regarding our regulatory plans, are forward-looking statements. These statements, including statements relating to the study design, timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
This press release was published by a CLEAR® Verified individual.
Dolby Laboratories (DLB) offers a compelling risk-reward profile with high margins, robust free cash flow, and a reasonable valuation. DLB's intrinsic value is estimated near $80 per share, implying 36% upside from current levels and supporting a double-digit annual return outlook. Growth is driven by expanding automotive, mobile, and streaming partnerships, with 93% of sales from licensing and strong IP protection.
, /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, will release financial results for the second quarter (Q2) fiscal year 2026 after the close of regular trading on Thursday, April 30, 2026.
Members of Dolby management will lead a conference call open to all interested parties to discuss Q2 fiscal year 2026 financial results for Dolby Laboratories at 2:00 p.m. PT (5:00 p.m. ET) on Thursday, April 30, 2026.
The conference call can be accessed by registering online at Dolby Laboratories Q2 Fiscal Year 2026 Financial Results, at which time registrants will receive dial-in information as well as a conference ID.
A live audio webcast of the conference call will be available at http://investor.dolby.com where it will be archived for one year.
About Dolby Laboratories
Dolby Laboratories (NYSE: DLB) is a world leader in immersive entertainment. From movies and TV, to music, sports, gaming, and beyond, Dolby transforms the science of sight and sound into spectacular experiences for billions of people worldwide across all their favorite devices. We partner with artists, storytellers, and the brands you love to transform entertainment and digital experiences through groundbreaking innovations like Dolby Atmos, Dolby Vision, Dolby Cinema, and Dolby OptiView.
Dolby, Dolby Atmos, Dolby Vision, Dolby Cinema, Dolby OptiView, and the double-D symbol are among the registered and unregistered trademarks of Dolby Laboratories in the United States and/or other countries.
Investor Contact:
Peter Goldmacher
Dolby Laboratories
[email protected]
Dolby Laboratories (NYSE:DLB – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $90.75.
Several research firms recently weighed in on DLB. Weiss Ratings reissued a “hold (c-)” rating on shares of Dolby Laboratories in a research note on Friday, March 27th. Rosenblatt Securities reissued a “buy” rating and issued a $85.00 target price on shares of Dolby Laboratories in a research note on Friday, January 30th. Barrington Research reduced their price objective on shares of Dolby Laboratories from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Monday, January 26th. Finally, Wall Street Zen cut shares of Dolby Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st.
Check Out Our Latest Research Report on Dolby Laboratories
Dolby Laboratories Stock Performance Shares of DLB stock opened at $64.63 on Friday. The company has a market capitalization of $6.17 billion, a P/E ratio of 26.06 and a beta of 0.86. The company’s 50 day moving average price is $62.97 and its two-hundred day moving average price is $64.94. Dolby Laboratories has a 52 week low of $57.62 and a 52 week high of $78.28.
Dolby Laboratories (NYSE:DLB – Get Free Report) last posted its quarterly earnings data on Thursday, January 29th. The electronics maker reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.07. Dolby Laboratories had a net margin of 17.97% and a return on equity of 11.50%. The company had revenue of $346.71 million for the quarter, compared to the consensus estimate of $341.26 million. During the same period last year, the company earned $1.14 earnings per share. The firm’s revenue was down 2.8% compared to the same quarter last year. Analysts forecast that Dolby Laboratories will post 2.94 earnings per share for the current year.
Dolby Laboratories Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 18th. Shareholders of record on Tuesday, February 10th were given a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Tuesday, February 10th. Dolby Laboratories’s payout ratio is 58.06%.
Insiders Place Their Bets In other news, SVP Shriram Revankar sold 3,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $66.14, for a total value of $198,420.00. Following the completion of the sale, the senior vice president owned 83,218 shares of the company’s stock, valued at approximately $5,504,038.52. The trade was a 3.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Ryan Nicholson sold 2,667 shares of the business’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $66.38, for a total transaction of $177,035.46. Following the completion of the sale, the chief accounting officer directly owned 36,956 shares of the company’s stock, valued at approximately $2,453,139.28. The trade was a 6.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 37.93% of the company’s stock.
Institutional Investors Weigh In On Dolby Laboratories A number of institutional investors have recently modified their holdings of the business. Paragon Capital Management Inc. bought a new stake in shares of Dolby Laboratories in the first quarter valued at about $1,306,000. Diversified Trust Co boosted its position in shares of Dolby Laboratories by 49.2% in the first quarter. Diversified Trust Co now owns 13,118 shares of the electronics maker’s stock valued at $788,000 after acquiring an additional 4,328 shares during the period. Hsbc Holdings PLC boosted its position in shares of Dolby Laboratories by 5.0% in the fourth quarter. Hsbc Holdings PLC now owns 6,301 shares of the electronics maker’s stock valued at $406,000 after acquiring an additional 301 shares during the period. Rockefeller Capital Management L.P. boosted its position in shares of Dolby Laboratories by 292.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 3,732 shares of the electronics maker’s stock valued at $240,000 after acquiring an additional 2,781 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Dolby Laboratories by 73,900.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,480 shares of the electronics maker’s stock valued at $95,000 after acquiring an additional 1,478 shares during the period. Institutional investors own 58.56% of the company’s stock.
Dolby Laboratories Company Profile (Get Free Report)
Dolby Laboratories, Inc is a global leader in audio and imaging technologies, specializing in the development, licensing and deployment of solutions that enhance entertainment and communications experiences. The company’s core business revolves around creating advanced audio codecs, noise reduction systems and spatial sound technologies for a wide range of applications, including cinema, broadcast, gaming, streaming and personal devices. Dolby’s licensing model enables consumer electronics manufacturers, content creators and service providers to integrate its technologies into products such as televisions, smartphones, home theater systems and set-top boxes.
Among its flagship innovations are Dolby Atmos, an immersive audio format that delivers three-dimensional soundscapes for theaters and home systems; Dolby Digital and Dolby Digital Plus, widely adopted audio compression formats for broadcast and streaming; and Dolby Vision, a high-dynamic-range imaging technology that expands color, contrast and brightness in displays.
See Also Five stocks we like better than Dolby Laboratories
Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEPerpetua Resources Corp. (NASDAQ:PPTA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
NEXT HEADLINE »Apple Hospitality REIT, Inc. (NYSE:APLE) Receives Consensus Recommendation of “Hold” from Brokerages
SAN FRANCISCO, April 30, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB) today announced the company's financial results for the second quarter of fiscal 2026. "We continue to strengthen our position and create growth opportunities across existing and new business areas," said Kevin Yeaman, President and CEO, Dolby Laboratories.
Dolby Laboratories (DLB) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $1.31 per share. This compares to earnings of $1.34 per share a year ago.
The headline numbers for Dolby Laboratories (DLB) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Dolby Laboratories (DLB 0.78%) stock tumbled 9.8% through 9:45 a.m. ET Friday despite beating on top and bottom lines in its fiscal Q2 2026 earnings report last night.
Heading into the report, analysts forecast the audio tech powerhouse would earn $1.33 per share on quarterly sales of $385.8 million. In fact, Dolby earned $1.37 per share, pro forma, on $396 million in sales.
Image source: Getty Images.
Dolby Q2 earnings The news wasn't quite as good as that makes it sound -- actual earnings per share, as calculated under generally accepted accounting principles (GAAP), were only $0.99, and the "$1.37" figure was non-GAAP. But even so, Dolby beat expectations, growing sales 8% year over year and earnings 5% year over year.
The news certainly could have been worse.
Unfortunately, the news on guidance was worse.
Today's Change
(
-0.78
%) $
-0.41
Current Price
$
52.32
What's next for Dolby stock A lot worse.
Dolby wrapped up its earnings report with a warning that non-GAAP profit will be only about $0.63 per share in Q3 (which is already underway) -- about a third less than the $0.98 per share Wall Street was anticipating. Full-year earnings could still hit the mark, with Dolby forecasting total 2026 non-GAAP profit between $4.30 and $4.45 per share, slightly ahead of Wall Street estimates.
Still, when measured under GAAP, Dolby expects to earn no more than $0.34 per share in Q3 and no more than $2.81 per share for the year. That's a steep sequential decline for the quarter, and for the year, it values Dolby stock at least 20 times earnings -- and possibly even higher.
For a stock growing sales and earnings only in the mid-single digits, that sounds like too high a price to pay.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Dolby Laboratories. The Motley Fool has a disclosure policy.
Dolby Labs is rated a 'BUY' with a conservative $80/share price target, reflecting 17–25% annualized upside potential through 2028. DLB trades at a rare sub-15x P/E, supported by robust patent-driven recurring revenue, high margins, and a net cash balance exceeding $500M. Despite cyclical end-market exposure and recent earnings volatility, DLB's technology leadership and dominant licensing position underpin long-term revenue security.
SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced that management will present at the following investor conferences: Kevin Yeaman, President and CEO, will host a presentation at the William Blair 46th Annual Growth Stock Conference in Chicago, Illinois on Wednesday, June 3, 2026, at 10:00 AM CT (11:00 AM ET). Robert Park, Senior Vice President and Chief Financial Officer, will host a presentation at the Baird Global Consumer, Technology and Services Conference in New York, New York on Thursday, June 4, 2026 at 9:40 AM ET.
SAN FRANCISCO, May 20, 2026 /PRNewswire/ -- Dolby Laboratories (NYSE: DLB), a leader in immersive entertainment, has earned two of the automotive industry's most prestigious supplier honors from General Motors: the 2025 Supplier of the Year and the Overdrive Award — GM's highest supplier recognition. It marks the first time Dolby has received either distinction, a milestone that reflects the company's leadership in redefining the in-car entertainment experience through innovations like Dolby Atmos.
/PRNewswire/ -- Dolby Laboratories (NYSE: DLB), a leader in immersive entertainment, and rednote, the leading lifestyle interest community, today announced
As theranostics adoption acceleratesi and radiopharmaceutical demand grows,ii healthcare systems are under increasing pressure to scale nuclear medicine operat
Arista Networks (NYSE: ANET), a leader in modern AI fabric networking, today announced the Arista [url="]7060XE7 Series[/url], a new portfolio of 1.6T networki
The Zacks Audio Video Production industry is facing quite a few challenges. Hardware demand remains cyclical and sensitive to consumer spending. Global macroeconomic uncertainty amid escalating trade tensions, tariffs and associated inflationary pressure is likely to keep consumer spending in check. This does not bode well for the participants. A highly promotional environment and stiff competition from importers of comparatively low-priced devices are denting margins. Online accessibility of recording equipment and the availability of distribution channels on the Internet are additional headwinds.
Nonetheless, participants like Sony Group Corporation (SONY - Free Report) , Dolby Laboratories, Inc. (DLB - Free Report) , and Sonos Inc. (SONO - Free Report) are likely to benefit from investments in cutting-edge technology solutions that drive enhanced communication experiences. The industry is moving into a phase that is marked by the convergence of content creation, immersive media (spatial audio, AR/VR and 3D video) and AI-driven workflows. Streaming, creator content, gaming, spatial audio and AI-powered tools are reimagining value creation across the industry. Rapid technological advances, such as 4K, 8K and immersive audio formats, are boosting the demand for new devices, which bodes well for participants like Dolby. The players also stand to gain as they increase focus on direct-to-customer sales channels.
Industry Description The Zacks Audio Video Production industry comprises television, speaker, video player and camcorder manufacturers. It includes companies that offer gaming consoles, drones and high-end cameras for individuals and industrial markets. These firms provide state-of-the-art audio, imaging and voice technologies that enhance entertainment and communication experiences. Some industry participants develop audio and imaging products, including digital cinema servers and products for film production and entertainment industries. Apart from providing theatrical and television production services for cinema exhibitions, broadcast and home entertainment, these companies work with film studios, content creators, broadcasters and video game designers. Some prominent players are present in the music and image-based software markets worldwide.
4 Trends Shaping the Future of the Audio-Video Production Industry Technological Advancement to Spur Growth: From rapid technological advances like 4K, 8K and immersive audio formats, the demand for high-resolution visual and audio experiences is a major growth driver. The rise of streaming or OTT platforms is fueling this trend, as consumers and businesses seek to recreate a cinematic atmosphere at home. Gaming is another catalyst, as PC and console gamers now seek enhanced visuals and immersive sound design. The rise of the creator economy is also fueling the demand for enhanced cameras and editing tools. Industry players like GoPro are benefiting from this trend, as its cameras are popular among creators. Automotive audio represents another lucrative opportunity as vehicles become more software-driven and experience-focused.
Increasing Demand for Premium Entertainment: The industry performed well despite drastic changes in how media is consumed and distributed. The rise in demand for premium entertainment from record labels, TV producers and advertisers is likely to stoke profitable growth. Strong demand across all regions with a more direct-to-consumer, subscription-centric model bodes well for industry participants.
Macroeconomic Headwinds Likely to Hurt Consumer Demand: The global macroeconomic uncertainty amid escalating trade tensions and tariffs, and associated inflationary pressures, is likely to keep consumer spending, especially discretionary purchases, in check. While companies keep investing in market share gains and supply-chain resilience, a shortage of critical hardware components due to the disruption in the supply chain could hurt revenues in the near term. Fluctuations in commodity pricing for different components are additional concerns. Elevated promotional activity to boost sales amid weak spending is also affecting the performance of these industry participants.
Aggressive Competition: In the United States, smart-connected televisions, microphones and speaker enclosures are the most popular electronic devices among customers. However, U.S.-based manufacturers of audio and video systems face intense competition from importers of comparatively low-priced devices, particularly from China, Vietnam and Mexico. These firms face stiff competition across all end markets, often leading to intense price wars and margin contraction.
Zacks Industry Rank Indicates Bleak Prospects The Zacks Audio Video Production industry is housed within the broader Zacks Consumer Discretionary sector. It currently has a Zacks Industry Rank of #177, placing it in the bottom 28% of more than 247 Zacks industries.
The group’s Zacks Industry Rank, which is the average of the Zacks Rank of all the member stocks, indicates bleak near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by more than two to one.
Before we present a few audio-video production stocks you may want to consider for your portfolio, let’s look at the industry’s recent stock market performance and valuation picture.
Industry Lags the Sector & the S&P 500 The Zacks Audio Video Production industry lags the broader Zacks Consumer Discretionary sector and the S&P 500 composite in the past year.
The industry has lost 14.8% over this period against the S&P 500’s 26.6% return. The broader sector has edged down 12.7% over the same timeframe.
One-Year Price Performance
Industry's Current Valuation Price-to-earnings is commonly used for valuing audio-video production stocks. The industry has a forward 12-month P/E of 16.45X compared with the S&P 500’s 21.43X. It is below the sector’s forward 12-month P/E of 16.8X.
In the past five years, the industry has traded as high as 23.92X and as low as 15.43X, with a median of 19.95X, as the chart below shows.
Price-to-Earnings Forward Ratio (Past Five Years)
3 Audio Video Production Stocks to Watch Sony Group Corporation: The Japan-based conglomerate designs, manufactures, and sells several consumer and industrial electronic equipment. The company’s product roster comprises audio and video equipment, televisions, network services, game hardware and software, mobile phones and image sensors.
Strategic focus on entertainment and intellectual property continues to support Sony’s long-term growth strategy. Sony continues to expand its ecosystem through PlayStation, Crunchyroll, Music and Pictures while leveraging cross-platform collaborations. Crunchyroll surpassed 21 million paid subscribers by March 2026 and now offers more than 50,000 episodes in multiple languages.
Sony’s G&NS segment continues to benefit from higher user engagement and recurring digital revenues despite softer hardware demand. Monthly active users on PlayStation reached 125 million in March 2026, while total gameplay time increased year over year. Fiscal 2025 G&NS operating income increased 12% to ¥463.3 billion despite large Bungie-related impairment charges. Growth in network services, third-party software sales and favorable forex dynamics supported profitability. For fiscal 2026, Sony expects segment operating income to rise further to ¥600 billion as it focuses on long-term user monetization and service expansion.
Sony faces intense competition in each of its product lines, including television, gaming platform and smartphone, around the world. Tariff uncertainty, weak hardware demand and execution risks in newer investments could continue limiting the company’s upside potential in the near term.
At present, SONY carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for fiscal 2026 bottom line is pegged at $1.28 per share, down 2 cents in the past seven days. Shares have plunged 17.8% in the past year.
Price & Consensus: SONY
Dolby: San Francisco-based Dolby develops audio and imaging technologies that revolutionize entertainment for user-generated content, TV shows, films, music and gaming. Dolby continues to see strong engagement across its ecosystem of creators, distributors and device OEMs for its Dolby Atmos and Dolby Vision technologies. For fiscal 2026, management continues to expect Dolby Atmos, Dolby Vision and imaging patents to grow about 15% and represent nearly half of licensing revenues.
Dolby is extending its presence in the automotive market, driven by strong demand from OEMs to elevate in-car entertainment quality. It also previously announced a collaboration with Qualcomm to integrate Dolby Atmos and Dolby Vision into the latter’s Gen 5 Snapdragon Automotive platform. Integrations like these are aimed at expanding its footprint into the auto ecosystem.
Dolby is also building new revenue streams. The video distribution program, a patent licensing pool for imaging patents for content streamers, continues to gain traction with 40 licensors onboarded. At the same time, Dolby OptiView represents an emerging opportunity in personalized sports streaming, with early customer wins such as Genius Sports and William Hill.
Dolby maintained its full-year fiscal 2026 guidance, indicating stable business trends. The company expects total revenues in the range of $1.4 billion to $1.45 billion.
However, Dolby expects the PC segment to decline, primarily due to lower unit sales in the broader PC market. Macroeconomic uncertainties, including inflation, changes in consumer spending, volatility in memory pricing, and broader supply chain dynamics, remain concerns.
At present, DLB carries a Zacks Rank #3.The Zacks Consensus Estimate for its fiscal 2026 bottom line is pegged at $4.31 per share, unchanged in the past seven days. Shares have plunged 28.1% in the past year.
Price & Consensus: DLB
Sonos: Headquartered in Santa Barbara, CA, Sonos operates as a consumer electronics company that is primarily involved in the manufacturing of speakers with immersive sound experiences.Product innovation is reaccelerating after a deliberate pause, with launches in the pipeline for the second half of fiscal 2026. The company is benefiting from a strong product pipeline, including new launches such as Sonos Play and Era 100 SL, which are designed both to attract new customers and deepen engagement within its existing installed base. The company is also planning Amp Multi for the professional installer channel later in fiscal 2026 and describes an active pipeline across both hardware and software.
Sonos is also refining its go-to-market strategy while expanding geographically to tap underpenetrated international markets. In the fiscal second quarter, APAC revenue grew 25% year over year, EMEA jumped 21% and the Americas grew 2%.
Management guided third-quarter fiscal 2026 revenues of $355 million to $375 million and adjusted EBITDA of $20 million to $48 million, reinforcing its view that the second half will be stronger than the first.
Management has called out higher memory costs as a cause for gross margin risk as the industry shifts supply toward newer memory standards. In the fiscal second quarter, higher memory costs were about a 200-basis-point drag on gross margin. Management expects roughly a 400-basis-point year-over-year drag in its third-quarter fiscal 2026 gross margin outlook. It expects second-half gross margin to run below the prior year level, even as it pursues mitigation actions.
At present, SONO carries a Zacks Rank #3. The Zacks Consensus Estimate for its fiscal 2026 bottom line is pegged at $1.20 per share, unchanged in the past 30 days. The company’s shares have gained 52.6% in the past year.
